Suppr超能文献

血浆中接触系统激活的起始依赖于因子 XII 的自身激活,而非因子 XII 对激肽释放酶裂解的易感性增强。

Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage.

作者信息

Citarella F, Wuillemin W A, Lubbers Y T, Hack C E

机构信息

Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Academic Medical Centre, University of Amsterdam.

出版信息

Br J Haematol. 1997 Oct;99(1):197-205. doi: 10.1046/j.1365-2141.1997.3513165.x.

Abstract

Various mechanisms have been hypothesized to explain the initiation of contact system activation in plasma. We investigated the capability of dextran sulphate (DS) of different molecular weights to initiate contact system activation in normal human plasma, and compared this with their capability to support factor XII autoactivation and to enhance factor XII susceptibility for cleavage by kallikrein. Dextran sulphate of Mr 500,000 (DS500) and 50,000 (DS50) was able to initiate contact system activation in plasma (determined by measuring the amount of factor XIIa-C1-inhibitor, kallikrein-C1-inhibitor and factor XIa-C1-inhibitor complexes generated) as well as to support factor XII autoactivation and to enhance factor XII susceptibility for cleavage by kallikrein (as measured with amidolytic assays using purified proteins). In contrast, dextran sulphate of Mr 15,000 (DS15) and 5000 (DS5) neither induced contact system activation in plasma, nor supported autoactivation of factor XII, although both of these DS species enhanced the rate of activation of factor XII by kallikrein in the purified system. Based on these properties (i.e. binding of factor XII without inducing autoactivation), DS15 and DS5 were predicted to be inhibitors of contact system activation induced in plasma by DS500, which indeed was observed. We conclude that enhanced factor XII susceptibility for kallikrein activation and factor XII autoactivation are distinct phenomena, the latter being necessary to support activation of the contact system in plasma.

摘要

人们已经提出了各种机制来解释血浆中接触系统激活的起始过程。我们研究了不同分子量的硫酸葡聚糖(DS)在正常人血浆中引发接触系统激活的能力,并将其与它们支持因子 XII 自动激活以及增强因子 XII 对激肽释放酶切割敏感性的能力进行了比较。分子量为 500,000(DS500)和 50,000(DS50)的硫酸葡聚糖能够在血浆中引发接触系统激活(通过测量生成的因子 XIIa-C1 抑制剂、激肽释放酶-C1 抑制剂和因子 XIa-C1 抑制剂复合物的量来确定),也能够支持因子 XII 自动激活并增强因子 XII 对激肽释放酶切割的敏感性(使用纯化蛋白通过酰胺水解测定法测量)。相比之下,分子量为 15,000(DS15)和 5000(DS5)的硫酸葡聚糖既不会在血浆中诱导接触系统激活,也不支持因子 XII 的自动激活,尽管这两种 DS 在纯化系统中都能增强激肽释放酶对因子 XII 的激活速率。基于这些特性(即结合因子 XII 而不诱导自动激活),预计 DS15 和 DS5 是 DS500 在血浆中诱导的接触系统激活的抑制剂,实际观察结果确实如此。我们得出结论,因子 XII 对激肽释放酶激活的敏感性增强和因子 XII 自动激活是不同的现象,后者是支持血浆中接触系统激活所必需的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验